ML346: A Novel Modulator of Proteostasis for Protein Conformational Diseases

Barbara Calamini  1 ,  Maria Catarina Silva  1  2 ,  Franck Madoux  3 ,  Darren M. Hutt  4 ,  Shilpi Khanna  5 ,  Monica A. Chalfant  4 ,  Christophe Allais  6 ,  Souad Ouizem  6 ,  Sanjay A. Saldanha  3 ,  Jill Ferguson  3 ,  Becky A. Mercer  3 ,  Cameron Michael  7 ,  Bradley D. Tait  5 ,  Dan Garza  5 ,  William E. Balch  4 ,  William R. Roush  6 ,  Richard I. Morimoto  1 ,  Peter Hodder  3
Affiliations
  • 1. Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL, USA
  • 2. Faculty of Sciences, Centre for Biodiversity, Functional and Integrative Genomics; (BioFIG), University of Lisboa, Lisboa, Portugal
  • 3. Scripps Research Institute Molecular Screening Center, Lead Identification Division, The Scripps Research Institute, Scripps Florida, Jupiter, Florida, USA
  • 4. Department of Cell Biology and Chemical Physiology, Institute for Childhood and Neglected Diseases, The Scripps Research Institute, La Jolla, CA, USA
  • 5. Proteostasis Therapeutics Inc., Cambridge, MA, USA
  • 6. Department of Chemistry, The Scripps Research Institute, Scripps Florida
  • 7. Discovery Biology, Drug Metabolism and Pharmacokinetics, The Scripps Research Institute Florida
PMID: 23833797
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18669
    ML346
    98.25%, Hsp70 Activator
    target: HSP
    Research Areas: Cancer